Making aspirin work; standing up to lung cancer 6abc.com, PA - Nov 30, 2008 Lung cancer kills more Americans than breast, prostate, colon, liver, kidney and skin cancers combined. Ambrose says, "We've got to step back, ...
Llew Keltner ? Battling solid tumours with light Pharmaceutical Technology Europe, UK - Also in preclinical stages are studies with Litx in prostate cancer and cutaneous vascular malformations. Q7: What are the company's plans for the future? ...
FDA to review Watson's longer-lasting cancer drug BusinessWeek - Nov 13, 2008 Watson Pharmaceuticals said federal health officials should make a decision on a long-lasting version of its prostate cancer drug Trelstar by third quarter ...WPI
Big money to be made in biotech stocks Stockhouse, Canada - Dendreon has been working on a promising prostate cancer drug, Provenge, for a few years. About two years ago, when the FDA found Provenge to be ?reasonably ...
Dendreon Reports Third Quarter 2008 Financial Results MarketWatch - Nov 7, 2008 The multicenter trial is enrolling 120 patients with metastatic, androgen independent prostate cancer. * Initiated a Phase 2 trial of PROVENGE in men with ...DNDN
Source: Google News
Recent News and Articles on the Keywords: cancer + fda + prostate Related to the article below (Last Update: 8/7/2008)
The FDA's Black Box Forbes, NY - Last year the agency rejected a prostate cancer treatment called Provenge from Dendreon (nasdaq: DNDN - news - people ) after an advisory panel voted 13-4 ...SGP - OTC:SHRGY
PSA test: Don't do it, say angry men Los Angeles Times, CA - Aug 4, 2008 Many of these men, guests invited by a fledgling group trying to get the word out that they think the standard screening test for prostate cancer is a bad ...
Hollis-Eden Pharmaceuticals Reports on Progress in Drug ... Business Wire (press release), CA - Hollis-Eden has commenced a Phase I/II clinical trial with its oral drug candidate APOPTONE? (HE3235) in late-stage prostate cancer patients who have failed ...HEPH
Pathwork First to Net FDA OK for Cancer of Unknown Primary Dx Pharmacogenomics Reporter (subscription), NY - By Turna Ray By being the first to launch an FDA- and CLIA-approved test designed to help physicians determine cancer type in a tumor, Pathwork Diagnostics ...
Guiding Lasers To Their Target Science Daily (press release) - Aug 5, 2008 A Houston-based company has developed an MRI-guided system that has been tested and is now FDA-approved. Laser induced thermal therapy (LITT) destroys ...
Treating an enlarged prostate Abilene Reporter-News, TX - Aug 4, 2008 Because PSA can signal the presence of prostate cancer, alpha-reductase inhibitors might hide prostate cancer or delay its detection. ...
Serum Proteomic Patterns for Detection of Prostate Cancer - EF Petricoin, DK Ornstein, CP Paweletz, A Ardekani … - jnci, 2002 - jnci.oxfordjournals.org ... Santiago; CB Simone, Simone Protective Cancer Institute, Lawrenceville ... e-mail:
petricoin{at}cber.fda.gov ... Pathologic states within the prostate may be reflected ...
Insulin-like Growth Factors and Prostate Cancer - M Pollak, W Beamer, JC Zhang - Cancer and Metastasis Reviews, 1998 - Springer ... with FDA approval of tamoxifen for breast cancer risk reduction in women with specified
risk pro- file, and with an ongoing large prostatecancer preven- tion ...
PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCER - JW MOUL - The Journal of Urology, 2000 - Elsevier ... Flutamide was the first FDA approved antiandrogen in the United States and since ...
plus leuprolide versus placebo and leuprolide in stage D2 prostatecancer cases ...
Source: Google Scholar
FDA Approves Advanced Prostate Cancer Drug
The US Food and Drug Administration has approved a new drug to treat men with advanced prostate cancer who cannot be treated with other therapies. Abarelix (marketed as Plenaxis by Praecis Pharmaceuticals) will be available only through certain physicians, because of the risk of serious side effects.
The drug is a hormone therapy intended for men whose cancer is causing problems like urinary difficulties, bone pain, or pressure on the spinal cord. The patients must also be unable to take other hormone therapies, and unable or unwilling to have surgical castration (removal of the testicles).
About 5% to 10% of men with prostate cancer have the type of advanced disease that would make them eligible for treatment with abarelix.
The drug can cause serious -- and even life-threatening -- allergic reactions in some patients, including low blood pressure and fainting, swelling of the face, throat or tongue, and breathing difficulties. For this reason, only doctors who are participating in the manufacturer's risk management program will be able to prescribe and administer the drug.
Abarelix is given as an injection into the buttocks every two weeks for the first month, then every four weeks after that. Men who receive the drug must remain in the doctor's office for at least 30 minutes after the shot, to be sure no allergic reaction occurs.
Other possible side effects include hot flashes, problems sleeping, pain, breast enlargement or breast pain, and constipation. The drug can also cause changes in the liver, so liver function must be monitored regularly.
Abarelix is a new type of drug known as a luteinizing hormone-releasing hormone (LHRH) antagonist. It works by lowering levels of testosterone, a male hormone that can cause prostate cancer to grow. Men who take the drug need to have their testosterone levels checked every two months or so, to be sure the medication is still working.
